Synthetic guide sequence to generate CRISPR-Cas9 entry strains in .

MicroPubl Biol

School of Biomolecular and Biomedical Science, University College Dublin, Dublin, Ireland.

Published: July 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

CRISPR/Cas9 genome editing has become an important and routine method in research to generate new mutants and endogenously tag genes. One complication of CRISPR experiments is that the efficiency of single-guide RNA sequences can vary dramatically One solution to this problem is to create an intermediate entry strain using the efficient and well-characterised guide RNA sequence. This "d10 entry strain" can then be used to generate your knock-in of interest. However, the sequence is not always suitable when creating an entry strain. For example, if your gene of interest is closely linked to on LGII or if you want to use the as a co-CRISPR marker for the creation of the entry strain then you can not use the sequence. This publication reports a synthetic guide sequence, GCTATCAACTATCCATATCG, that is not present in the genome and can be used to create entry strains. This guide sequence is demonstrated to be relatively robust with a knock-in efficiency that varies from 1-11%. While this is lower than the efficiency observed with entry strains, it is still sufficient for most applications. This guide sequence can be added to the CRISPR toolkit and is particularly useful for generating entry strains where the standard guide sequence is not suitable.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12296677PMC
http://dx.doi.org/10.17912/micropub.biology.001694DOI Listing

Publication Analysis

Top Keywords

guide sequence
20
entry strains
16
entry strain
12
synthetic guide
8
sequence
8
entry
8
sequence suitable
8
guide
5
sequence generate
4
generate crispr-cas9
4

Similar Publications

Metagenomic analyses of microbial communities have unveiled a substantial level of interspecies and intraspecies genetic diversity by reconstructing metagenome-assembled genomes (MAGs). The MAG database (MAGdb) boasts an impressive collection of 74 representative research papers, spanning clinical, environmental, and animal categories and comprising 13,702 paired-end run accessions of metagenomic sequencing and 99,672 high quality MAGs with manually curated metadata. MAGdb provides a user-friendly interface that users can browse, search, and download MAGs and their corresponding metadata information.

View Article and Find Full Text PDF

Purpose: Next-generation sequencing (NGS) has revolutionized cancer treatment by enabling comprehensive cancer genomic profiling (CGP) to guide genotype-directed therapies. While several prospective trials have demonstrated varying outcomes with CGP in patients with advanced solid tumors, its clinical utility in colorectal cancer (CRC) remains to be evaluated.

Methods: We conducted a prospective observational study of CGP in our hospital between September 2019 and March 2024.

View Article and Find Full Text PDF

Fetal magnetic resonance imaging (MRI) is a safe method of in-utero evaluation of fetal anomalies and a valuable adjunct to prenatal ultrasound. The utilization of rapid sequences reduces the impact of fetal motion and allows for high contrast resolution of fetal structures. A thorough understanding of fetal anatomy and a systematic approach to MRI interpretation are essential for accurate diagnosis of fetal head and neck anomalies.

View Article and Find Full Text PDF

Purpose: To assess modified folinic acid/leucovorin, fluorouracil, irinotecan, oxaliplatin (FOLFIRINOX; mFFX) versus gemcitabine/nab-paclitaxel (GnP) in de novo metastatic pancreatic ductal adenocarcinoma (PDAC) and explore predictive biomarkers.

Patients And Methods: Patients were randomly assigned 1:1 to mFFX or GnP with exclusion of germline pathogenic variants in or . The primary end point was progression-free survival (PFS) between arms with 0.

View Article and Find Full Text PDF

Interferon-induced senescent CD8 T cells reduce anti-PD1 immunotherapy efficacy in early triple-negative breast cancer.

Sci Transl Med

September 2025

Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Precision Cancer Medicine Center, Fudan University Shanghai Cancer Center, Shanghai 200032, P. R. China.

Triple-negative breast cancers (TNBCs) lack predictive biomarkers to guide immunotherapy, especially during early-stage disease. To address this issue, we used single-cell RNA sequencing, bulk transcriptomics, and pathology assays on samples from 171 patients with early-stage TNBC receiving chemotherapy with or without immunotherapy. Our investigation identified an enriched subset of interferon (IFN)-induced CD8 T cells in early TNBC samples, which predict immunotherapy nonresponsiveness.

View Article and Find Full Text PDF